A correlation analysis between tumor imaging changes and p-AKT and HSP70 expression in tumor cells after osteosarcoma chemotherapy

Ji,Feng; Lv,Ran; Zhao,Ting

doi:10.3892/ol.2017.7005

A correlation analysis between tumor imaging changes and p-AKT and HSP70 expression in tumor cells after osteosarcoma chemotherapy

Authors:
- Feng Ji
- Ran Lv
- Ting Zhao
View Affiliations

Affiliations: Department of Radiology, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China, Department of Medical Oncology, Liaocheng Tumor Hospital, Liaocheng, Shandong 252000, P.R. China
Published online on: September 20, 2017 https://doi.org/10.3892/ol.2017.7005
Pages: 6749-6753
Copyright: © Ji et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study sought to investigate osteosarcoma property changes after neoadjuvant chemotherapy and to analyze any correlation between changes with phospho-AKT (p-AKT) and heat shock protein 70 (HSP70) expression in osteosarcoma cells. Thirty patients with osteosarcoma treated at Liaocheng People's Hospital between January and October, 2016 were given an imaging examination before and after neoadjuvant chemotherapy to examine osteosarcoma tumor properties, with images scored. Immunohistochemistry was used to determine p-AKT and HSP70 expression levels, as well as tumor cell necrosis rate (TCNR), in specimens obtained before and after chemotherapy. The correlation between the imaging changes of osteosarcoma after chemotherapy and the expressions of p-AKT and HSP70 in tumor cells. Compared with pre-chemotherapy, the imaging scores of the 30 patients significantly increased after chemotherapy (P<0.05). The radiographic score of the TCNR ≥90% group was 11.3±0.5, which was significantly higher than that of the TCNR <90% group (8.7±0.3, P<0.05). p-AKT expression in osteosarcoma cells was found in 13.3% of samples (4/30 cases) after chemotherapy, which was significantly lower than prior to chemotherapy (73.3%, 22/30 cases, P<0.05). After chemotherapy, HSP70 expression in osteosarcoma cells was found in 6.7% of samples (2/30 cases), which was significantly lower than prior to chemotherapy (83.3%, 25/30 cases, P<0.05). p-AKT and HSP70 expression levels were found to be correlated with TCNR after chemotherapy (P<0.05). After chemotherapy, p-AKT and HSP70 expression levels demonstrated a positive correlation with TCNR. Tumor property changes, as uncovered by imaging, were significantly inversely correlated with tumor cell p-AKT and HSP70 expression after chemotherapy. Therefore, osteosarcoma properties, as determined through X-ray imaging, were closely related to p-AKT and HSP70 expression in osteosarcoma cells after neoadjuvant chemotherapy. The effect of chemotherapy can be evaluated by observing the above examination results.

View Figures

View References

1	Laux CJ, Berzaczy G, Weber M, Lang S, Dominkus M, Windhager R, Nöbauer-Huhmann IM and Funovics PT: Tumour response of osteosarcoma to neoadjuvant chemotherapy evaluated by magnetic resonance imaging as prognostic factor for outcome. Int Orthop. 39:97–104. 2015. View Article : Google Scholar : PubMed/NCBI
2	Kubo T, Furuta T, Johan MP, Adachi N and Ochi M: Percent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma: Systematic review and meta-analysis. Skeletal Radiol. 45:1235–1242. 2016. View Article : Google Scholar : PubMed/NCBI
3	Li H, Li XY, Bu J and Xiao T: How to explain the role of magnetic resonance imaging on evaluating tumour response of osteosarcoma to neoadjuvant chemotherapy? Int Orthop. 39:1031–1032. 2015. View Article : Google Scholar : PubMed/NCBI
4	Ji WP and He NB: Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma. Int J Clin Exp Pathol. 8:894–899. 2015.PubMed/NCBI
5	Hagleitner MM, Coenen MJ, Gelderblom H, Makkinje RR, Vos HI, de Bont ES, van der Graaf WT, Schreuder HW, Flucke U, van Leeuwen FN, et al: A first step towards personalized medicine in osteosarcoma: Pharmacogenetics as predictive marker of outcome after chemotherapy based treatment. Clin Cancer Res. 21:3436–3441. 2015. View Article : Google Scholar : PubMed/NCBI
6	Sarman H, Bayram R and Benek SB: Anticancer drugs with chemotherapeutic interactions with thymoquinone in osteosarcoma cells. Eur Rev Med Pharmacol Sci. 20:1263–1270. 2016.PubMed/NCBI
7	Li S, Sun W, Wang H, Zuo D, Hua Y and Cai Z: Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal. Tumour Biol. 36:1329–1338. 2015. View Article : Google Scholar : PubMed/NCBI
8	Wang X, Zheng H, Shou T, Tang C, Miao K and Wang P: Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: A network meta-analysis of randomized controlled trials. J Orthop Surg Res. 12:522017. View Article : Google Scholar : PubMed/NCBI
9	Zhu XZ and Mei J: Effect and mechanism analysis of siRNA in inhibiting VEGF and its anti-angiogenesis effects in human osteosarcoma bearing rats. Eur Rev Med Pharmacol Sci. 19:4362–4370. 2015.PubMed/NCBI
10	Ahn JH, Cho WH, Lee JA, Kim DH, Seo JH and Lim JS: Bone mineral density change during adjuvant chemotherapy in pediatric osteosarcoma. Ann Pediatr Endocrinol Metab. 20:150–154. 2015. View Article : Google Scholar : PubMed/NCBI
11	Byun BH, Kim SH, Lim SM, Lim I, Kong CB, Song WS, Cho WH, Jeon DG, Lee SY, Koh JS, et al: Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT. Eur Radiol. 25:2015–2024. 2015. View Article : Google Scholar : PubMed/NCBI
12	1Chang KJ, Kong CB, Cho WH, Jeon DG, Lee SY, Lim I and Lim SM: Usefulness of increased 18F-FDG uptake for detecting local recurrence in patients with extremity osteosarcoma treated with surgical resection and endoprosthetic replacement. Skeletal Radiol. 44:529–537. 2015. View Article : Google Scholar : PubMed/NCBI
13	Avril P, Le Nail LR, Brennan MÁ, Rosset P, De Pinieux G, Layrolle P, Heymann D, Perrot P and Trichet V: Mesenchymal stem cells increase proliferation but do not change quiescent state of osteosarcoma cells: Potential implications according to the tumor resection status. J Bone Oncol. 5:5–14. 2015. View Article : Google Scholar : PubMed/NCBI
14	Cai S, Zhang T, Zhang D, Qiu G and Liu Y: Volume-sensitive chloride channels are involved in cisplatin treatment of osteosarcoma. Mol Med Rep. 11:2465–2470. 2015. View Article : Google Scholar : PubMed/NCBI
15	Guo J, Glass JO, McCarville MB, Shulkin BL, Daryani VM, Stewart CF, Wu J, Mao S, Dwek JR, Fayad LM, et al: Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. Br J Cancer. 113:1282–1288. 2015. View Article : Google Scholar : PubMed/NCBI
16	Xiao X, Wang W, Zhang H, Gao P, Fan B, Huang C, Fu J, Chen G, Shi L, Zhu H, et al: Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma. Tumour Biol. 36:2427–2435. 2015. View Article : Google Scholar : PubMed/NCBI
17	Lee JA, Jeon DG, Cho WH, Song WS, Yoon HS, Park HJ, Park BK, Choi HS, Ahn HS, Lee JW, et al: Higher gemcitabine dose was associated with better outcome of osteosarcoma patients receiving gemcitabine-docetaxel chemotherapy. Pediatr Blood Cancer. 63:1552–1556. 2016. View Article : Google Scholar : PubMed/NCBI
18	Katagiri H, Sugiyama H, Takahashi M, Murata H, Wasa J, Hosaka S and Miyagi M: Osteosarcoma of the pelvis treated successfully with repetitive intra-arterial chemotherapy and radiation therapy: A report of a case with a 21-year follow-up. J Orthop Sci. 20:568–573. 2015. View Article : Google Scholar : PubMed/NCBI
19	Kleinerman E: Maximum benefit of chemotherapy for osteosarcoma achieved-what are the next steps? Lancet Oncol. 17:1340–1342. 2016. View Article : Google Scholar : PubMed/NCBI
20	Fang X, Jiang Y, Feng L, Chen H, Zhen C, Ding M and Wang X: Blockade of PI3K/AKT pathway enhances sensitivity of Raji cells to chemotherapy through down-regulation of HSP70. Cancer Cell Int. 13:482013. View Article : Google Scholar : PubMed/NCBI
21	Chatterjee M, Andrulis M, Stühmer T, Müller E, Hofmann C, Steinbrunn T, Heimberger T, Schraud H, Kressmann S, Einsele H, et al: The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica. 98:1132–1141. 2013. View Article : Google Scholar : PubMed/NCBI
22	Boon E, van der Graaf WT, Gelderblom H, Tesselaar ME, van Es RJ, Oosting SF, de Bree R, van Meerten E, Hoeben A, Smeele LE, et al: Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. Head Neck. 39:140–146. 2017. View Article : Google Scholar : PubMed/NCBI
23	Pan T, Li X, Xie W, Jankovic J and Le W: Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett. 579:6716–6720. 2005. View Article : Google Scholar : PubMed/NCBI